Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICE STUDY
2024-515039-31-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in type I cryoglobulinaemia, cryoglobulinaemia and monoclonal gammopathy of undetermined significance (MGUS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete clinical response rate of cryoglobulinemia vasculitis symptoms at week 20. Started Nov 2024; status: completed.
02
Drugs
isatuximab
03
Conditions
type I cryoglobulinaemiacryoglobulinaemiamonoclonal gammopathy of undetermined significance (MGUS)
Beyond the preview
Go deeper on 2024-515039-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515039-31-00.